AIC
SRPT icon

Archer Investment Corporation’s Sarepta Therapeutics SRPT Stock Holding History

Archer Investment Corporation’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-35
Closed -$3K – 638
2019
Q3 		$3K Hold
35
– – ﹤0.01% 425
2019
Q2 		$5K Hold
35
– – ﹤0.01% 387
2019
Q1 		$4K Sell
35
-551
-94% -$70.8K ﹤0.01% 406
2018
Q4 		$64K Buy
+586
New +$73.3K 0.06% 204

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Archer Investment Corporation's SRPT Position: Q4 2019 in Review

Archer Investment Corporation sold out of Sarepta Therapeutics (SRPT) in Q4 2019, closing a stake of 35 shares — an estimated $3K sold.

Archer Investment Corporation first reported a position in SRPT in Q4 2018 and held it in 4 quarters. The position peaked at $64K in Q4 2018. 390 funds tracked by Wall St. Rank hold SRPT as of Q4 2019.

  • Archer Investment Corporation reported no remaining Sarepta Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Archer Investment Corporation sold 35 Sarepta Therapeutics shares in Q4 2019, an estimated $3K.
  • Archer Investment Corporation first reported a position in Sarepta Therapeutics in Q4 2018 and held it in 4 quarters.
  • Archer Investment Corporation's Sarepta Therapeutics position peaked at $64K in Q4 2018.
  • 390 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2019.

Based on Archer Investment Corporation's 13F filing for Q4 2019, filed 20 Feb 2020.